Equities research analysts forecast that BioXcel Therapeutics (NASDAQ:BTAI) will post ($0.21) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for BioXcel Therapeutics’ earnings. The company is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that BioXcel Therapeutics will report full-year earnings of ($1.22) per share for the current financial year. For the next year, analysts expect that the firm will report earnings of ($2.03) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow BioXcel Therapeutics.
A number of equities research analysts recently weighed in on the company. Canaccord Genuity assumed coverage on BioXcel Therapeutics in a research note on Monday, April 2nd. They set a “buy” rating and a $21.00 price objective for the company. UBS started coverage on BioXcel Therapeutics in a research note on Monday, April 2nd. They set a “buy” rating and a $18.00 price objective for the company. Barclays started coverage on BioXcel Therapeutics in a research note on Monday, April 2nd. They set an “overweight” rating and a $15.00 price objective for the company. BMO Capital Markets started coverage on BioXcel Therapeutics in a research note on Monday, April 2nd. They set an “outperform” rating and a $23.00 price objective for the company. Finally, HC Wainwright started coverage on BioXcel Therapeutics in a research note on Thursday. They set a “buy” rating and a $25.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, BioXcel Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.40.
Shares of BTAI traded down $0.70 during mid-day trading on Friday, hitting $7.70. 39,801 shares of the stock were exchanged, compared to its average volume of 36,113. BioXcel Therapeutics has a 52-week low of $6.76 and a 52-week high of $11.94.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.